prelude therapeutics

prelude therapeutics

NASDAQ:PRLD

Chart

Detailed Quote

Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need.

Featured Articles and Interviews
Press Releases

Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering

Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research Annual Meeting 2026

The Conversation (0)